baricitinib (Olumiant)

following a full submission:

baricitinib (Olumiant®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.

SMC restriction: treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy who have failed at least one current systemic immunosuppressant due to intolerance, contraindication or inadequate disease control.

Four phase III studies demonstrated superiority of baricitinib in improving signs and symptoms of atopic dermatitis when compared with placebo, as monotherapy or in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.